The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Limiting the power of p53 through the ubiquitin proteasome pathway
Open accessAbstract
The ubiquitin proteasome pathway is critical in restraining the activities of the p53 tumor suppressor. Numerous E3 and E4 ligases regulate p53 levels. Additionally, deubquitinating enzymes that modify p53 directly or indirectly also impact p53 function. When alterations of these proteins result in increased p53 activity, cells arrest in the cell cycle, senesce, or apoptose. On the other hand, alterations that result in decreased p53 levels yield tumor-prone phenotypes. This review focuses on the physiological relevance of these important regulators of p53 and their therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“One of the best-studied such small molecules is Nutlin 3a, which binds Mdm2 and interferes with its ability to interact and degrade p53 (Vassilev et al. 2004).”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“Mdm2 is an E3 ubiquitin ligase of the RING finger class that regulates p53 stability and activity (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997; Marine and Lozano 2009).”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Mdm2 is an E3 ubiquitin ligase of the RING finger class that regulates p53 stability and activity (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997; Marine and Lozano 2009).”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“The p53 tumor suppressor maintains genomic integrity by primarily functioning as a sequence-specific DNA-binding transcription factor (Vousden and Prives 2009).”
BackgroundRING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Reintroduction of functionally active wild-type p53 negatively impacts tumor growth in mice (Martins et al. 2006; Xue et al. 2007; Wang et al. 2011; Li et al. 2014).”
BackgroundOncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 1×
“Mdm2 is an E3 ubiquitin ligase of the RING finger class that regulates p53 stability and activity (Haupt et al. 1997; Honda et al. 1997; Kubbutat et al. 1997; Marine and Lozano 2009).”
BackgroundTranscriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 1×
“On sensing unfavorable cellular conditions, p53 transactivates downstream targets to induce apoptosis, cell cycle arrest, or senescence in affected cells and stops them from further propagating the damage (Riley et al. 2008).”
BackgroundThe p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 1×
“Increased p53 activity has been implicated in aging defects (Tyner et al. 2002).”
BackgroundRescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Self-citationmdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 2×
“Single-nucleotide polymorphisms (SNPs) in Mdm2 have been discovered that regulate Mdm2 levels and impact p53 activity, contributing to tumor risk (Bond et al. 2004; Post et al. 2010; Knappskog et al. 2011).”
BackgroundSelf-citationRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 2×
“…compounds, based on a similar concept such as RITA (reactivation of p53 and induction of tumor cell apoptosis) and PRIMA (p53 reactivation and induction ofmassive apoptosis), have also yielded encouraging results in cell culture and xenograft experiments (Bykov et al. 2002; Issaeva et al. 2004).”
ResultMono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · cited 1×
“For example, low Mdm2 levels induce monoubiquitination and nuclear export of p53, while higher levels promote its polyubiquitination and degradation (Li et al. 2003).”
BackgroundMDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · cited 1×
“However, the RING domain of Mdm4 does not possess an analogous E3 ligase activity GENES & DEVELOPMENT 1743 (Shvarts et al. 1996; Stad et al. 2001).”
BackgroundUSP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637 · cited 1×
“Recent studies have also shown that USP10 deubiquitinates mutant p53 and thus may promote the oncogenic effects of mutant p53 in tumor cells (Yuan et al. 2010).”
BackgroundModeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“Reintroduction of functionally active wild-type p53 negatively impacts tumor growth in mice (Martins et al. 2006; Xue et al. 2007; Wang et al. 2011; Li et al. 2014).”
BackgroundMDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570 · cited 1×
“Physiological disruption of the interaction between p53 and Mdm2/Mdm4 also occurs upon post-translational modifications and impacts p53 ubiquitination (Prives and Hall 1999; Ito et al. 2002; Li et al. 2002; Chao et al. 2003, 2006; Xirodimas et al. 2004; Wang et al. 2009; Gannon et al. 2012).”
BackgroundParant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517 · cited 1×
“Mdm4 loss leads to a p53dependent embryo-lethal phenotype (Parant et al. 2001; Migliorini et al. 2002).”
BackgroundSelf-citationAcetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
p300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414 · cited 1×
“The histone acetyltransferase (HAT) p300 and its paralog, CBP (CREB-binding protein), are the first set of proteins identified to possess an intrinsic E4 activity toward p53 in vitro and in cell culture (Grossman et al. 1998).”
BackgroundDisruption of HAUSP gene stabilizes p53.
Cummins, J. M., Rago, C., Kohli, M., Kinzler, K. W., Lengauer, C., & Vogelstein, B. (2004) · Nature · doi:10.1038/nature02501 · Cited by 379
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361
MDM2 interacts with MDMX through their RING finger domains
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324
Migliorini, D., Denchi, E. L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P. G., & Marine, J.-C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5527-5538.2002 · Cited by 313
Trim24 targets endogenous p53 for degradation
Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292 · cited 3×
“Trim24 was identified as a p53-binding partner in screens using TAP-tagged p53 as the bait protein (Allton et al. 2009).”
BackgroundFeng, Z., Hu, W., Teresky, A. K., Hernando, E., Cordon-Cardo, C., & Levine, A. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708043104 · Cited by 264
Meulmeester, E., Maurice, M. M., Boutell, C., Teunisse, A. F. A. S., Ovaa, H., Abraham, T. E., Dirks, R. W., & Jochemsen, A. G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.024 · Cited by 260
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo
Francoz, S., Froment, P., Bogaerts, S., De Clercq, S., Maetens, M., Doumont, G., Bellefroid, E., & Marine, J.-C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508476103 · Cited by 260
Min, J.-N., Whaley, R. A., Sharpless, N. E., Lockyer, P., Portbury, A. L., & Patterson, C. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00296-08 · Cited by 256 · cited 1×
“CHIP / mice have atrophied thymi and display a reduced life span and accelerated aging phenotypes accompanied by accelerated cellular senescence and increased indication of oxidative stress (Min et al. 2008).”
BackgroundMdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256
Feng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236 · cited 1×
“However, knock-inmicewith lysineto-arginine mutations that prevent ubiquitination but do not modify charge at these six residues (p53-6KR) do not exhibit significantly increased p53 levels (Feng et al. 2005).”
BackgroundUbiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193 · cited 1×
“Disruption of Mdm2–Mdm4 interaction results in an embryolethal phenotype that is also p53-dependent (Huang et al. 2011; Pant et al. 2011).”
BackgroundKrummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187
Brooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186
Inactivation of HAUSP in vivo modulates p53 function.
Kon, N., Kobayashi, Y., Li, M., Brooks, C. L., Ludwig, T., & Gu, W. (2010) · Oncogene · doi:10.1038/onc.2009.427 · Cited by 176 · cited 2×
“However, theHausp knockout mouse is embryo-lethal ;6.5–7.5 dpc due to severe reduction of cell proliferation (Kon et al. 2010).”
BackgroundInfluentialThe role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo
Saville, M. K., Sparks, A., Xirodimas, D. P., Wardrop, J., Stevenson, L. F., Bourdon, J.-C., Woods, Y. L., & Lane, D. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403362200 · Cited by 158
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155
Self-citationCell Type- and Promoter-specific Roles of Ser18 Phosphorylation in Regulating p53 Responses
Chao, C., Hergenhahn, M., Kaeser, M. D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., & Xu, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306938200 · Cited by 141 · cited 1×
“Physiological disruption of the interaction between p53 and Mdm2/Mdm4 also occurs upon post-translational modifications and impacts p53 ubiquitination (Prives and Hall 1999; Ito et al. 2002; Li et al. 2002; Chao et al. 2003, 2006; Xirodimas et al. 2004; Wang et al. 2009; Gannon et al. 2012).”
BackgroundPant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134
Self-citationA High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development
Post, S. M., Quintás-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.010 · Cited by 127
Self-citationHaploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development
Terzian, T., Wang, Y., Van Pelt, C. S., Box, N. F., Travis, E. L., & Lozano, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00555-06 · Cited by 116
Self-citationGannon, H. S., Woda, B. A., & Jones, S. N. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.011 · Cited by 105 · cited 1×
“Physiological disruption of the interaction between p53 and Mdm2/Mdm4 also occurs upon post-translational modifications and impacts p53 ubiquitination (Prives and Hall 1999; Ito et al. 2002; Li et al. 2002; Chao et al. 2003, 2006; Xirodimas et al. 2004; Wang et al. 2009; Gannon et al. 2012).”
BackgroundValidation of MdmX as a therapeutic target for reactivating p53 in tumors
Garcia, D., Warr, M. R., Martins, C. P., Brown Swigart, L., Passegué, E., & Evan, G. I. (2011) · Genes & Development · doi:10.1101/gad.16722111 · Cited by 83 · cited 1×
“Based on mild phenotypes observed after Mdm4 inhibition in cell culture and animal models, it is argued that these may be less toxic (Garcia et al. 2011).”
BackgroundRoles of HAUSP-mediated p53 regulation in central nervous system development
Kon, N., Zhong, J., Kobayashi, Y., Li, M., Szabolcs, M., Ludwig, T., Canoll, P. D., & Gu, W. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.12 · Cited by 79 · cited 1×
“Neural cell-specific deletion of Hausp results in p53-dependent neonatal lethality, suggesting a tissue-specific role of Hausp in regulation of p53 (Kon et al. 2011).”
BackgroundWang, Y. V., Leblanc, M., Wade, M., Jochemsen, A. G., & Wahl, G. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.008 · Cited by 79
Cited by
Ubiquitylation at the crossroads of development and disease
Rape, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.83 · Cited by 614
Zhou, G., Liu, Z., & Myers, J. N. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25592 · Cited by 343
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Clinical Overview of MDM2/X-Targeted Therapies
Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Metadata
- Authors
- Pant, V., & Lozano, G.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-08-15
- Volume
- 28
- Issue
- 16
- Pages
- 1739-1751
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2026140625
- Cited by
- 167
- References
- 51
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.